Clinical Trials Logo

Imatinib Intolerant clinical trials

View clinical trials related to Imatinib Intolerant.

Filter by:
  • None
  • Page 1

NCT ID: NCT01206088 Completed - CML Clinical Trials

Tasigna in Glivec-resistant or Intolerant Patients in CML

Start date: February 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate efficacy and safety of nilotinib in patients with Imatinib resistant or intolerant CML-CP or AC. Efficacy evaluation will be made by Complete cytogenetic response rate(CCyR) at 12 months after nilotinib administration.